Two phase I studies of recombinant human IL-15 in combination with haploidentical NK cell infusions for solid tumors and AML showed improvements in in vivo expansion compared to historical reports of IL-2 mediated expansion [118]. This evidence concerns the gene IL2 and acute myeloid leukemia.